GAD-7 — Generalized Anxiety Disorder Scale: Scoring, Interpretation, and Clinical Use

The GAD-7 (Generalized Anxiety Disorder 7-item scale) is a brief, validated self-report questionnaire designed to screen for and measure the severity of generalized anxiety disorder (GAD). Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke, and colleagues, the GAD-7 was first published in 2006 in the journal Archives of Internal Medicine and has since become one of the most widely used anxiety screening instruments in clinical practice worldwide.

The tool consists of seven items that directly correspond to the diagnostic criteria for generalized anxiety disorder as outlined in the DSM-5-TR (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision). Each item asks respondents to rate how often they have been bothered by a specific anxiety symptom over the past two weeks. The GAD-7 is not a diagnostic instrument — it is a screening and severity measure that helps clinicians identify individuals who may benefit from further evaluation and track changes in anxiety symptoms over time.

Because of its brevity, psychometric strength, and ease of administration, the GAD-7 has been adopted across primary care, psychiatric settings, research studies, and integrated behavioral health programs. It is available in the public domain, meaning it can be used without permission or licensing fees.

The GAD-7 measures the frequency and severity of core anxiety symptoms associated with generalized anxiety disorder. The seven items assess the following experiences over the preceding two-week period:

• Feeling nervous, anxious, or on edge
• Not being able to stop or control worrying
• Worrying too much about different things
• Trouble relaxing
• Being so restless that it's hard to sit still
• Becoming easily annoyed or irritable
• Feeling afraid, as if something awful might happen

These items capture the hallmark features of GAD as defined in the DSM-5-TR: excessive anxiety and worry occurring more days than not, difficulty controlling worry, and associated symptoms such as restlessness, fatigue, difficulty concentrating, irritability, muscle tension, and sleep disturbance. While the GAD-7 does not cover every DSM-5-TR criterion (notably, it does not directly assess muscle tension, fatigue, difficulty concentrating, or sleep disturbance), it captures the core cognitive and somatic features that are most clinically salient.

Although designed primarily for generalized anxiety disorder, research has demonstrated that the GAD-7 has reasonable sensitivity for detecting other anxiety disorders as well, including panic disorder, social anxiety disorder, and post-traumatic stress disorder. This makes it a useful — though not specific — general anxiety screening tool. However, clinicians should understand that elevated GAD-7 scores do not pinpoint a specific anxiety disorder and always warrant further clinical evaluation to determine the precise diagnosis.

The GAD-7 was originally developed and validated in adult primary care populations. The initial validation study by Spitzer and colleagues (2006) enrolled 2,740 adult patients in 15 primary care clinics in the United States. Since then, the instrument has been validated across a wide range of populations and settings:

• Primary care patients — the original and most extensively studied population
• Psychiatric outpatients and inpatients
• College students and young adults
• Older adults — though some research suggests that older populations may underreport certain symptoms
• Perinatal populations — the GAD-7 is commonly used alongside the Edinburgh Postnatal Depression Scale (EPDS) in prenatal and postpartum screening
• Medical populations — including patients with chronic pain, cancer, cardiovascular disease, and other medical conditions where anxiety is a common comorbidity
• Diverse cultural and linguistic groups — the GAD-7 has been translated into more than 100 languages and validated in numerous international samples

For adolescents aged 12–17, a modified version called the GAD-7 (adolescent) has been studied, though some clinicians and researchers prefer the Screen for Child Anxiety Related Disorders (SCARED) or other age-appropriate instruments for younger populations. The GAD-7 is generally not recommended for children under 12 without adaptation.

Notably, the GAD-7 is designed as a population-level screening tool, not a stand-alone diagnostic instrument. It is most effective when integrated into a broader clinical assessment that includes a thorough diagnostic interview.

The GAD-7 is a self-administered questionnaire that takes approximately one to two minutes to complete. It can be administered on paper, electronically through patient portals and electronic health records (EHRs), or verbally by a clinician in situations where self-report is not feasible.

Each of the seven items is rated on a 4-point Likert scale based on how often the respondent has been bothered by the symptom over the past two weeks:

• 0 — Not at all
• 1 — Several days
• 2 — More than half the days
• 3 — Nearly every day

The total score is calculated by summing all seven items, producing a score ranging from 0 to 21. The established severity thresholds are:

• 0–4: Minimal anxiety
• 5–9: Mild anxiety
• 10–14: Moderate anxiety
• 15–21: Severe anxiety

A score of 10 or above is the most commonly used cut-point for identifying clinically significant anxiety that warrants further evaluation. In the original validation study, a cut-point of 10 yielded a sensitivity of 89% and a specificity of 82% for detecting generalized anxiety disorder. Some clinical settings use a lower threshold of 8 to increase sensitivity, particularly in populations where anxiety may be underreported or where the consequences of missing cases are significant.

The GAD-7 also includes an optional supplementary question that is not scored: "If you checked any problems, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?" Response options range from "not difficult at all" to "extremely difficult." This functional impairment question provides additional clinical context and aligns with the DSM-5-TR requirement that symptoms cause clinically significant distress or impairment in functioning.

The GAD-7 is one of the most extensively validated anxiety screening instruments in clinical research. Its psychometric properties have been evaluated in hundreds of studies across diverse populations and settings.

Internal consistency is excellent. The original validation study reported a Cronbach's alpha of 0.92, indicating that the seven items reliably measure a single underlying construct. Subsequent studies have consistently replicated this finding, with alpha values typically ranging from 0.89 to 0.93 across different samples.

Test-retest reliability is strong. Spitzer et al. (2006) reported an intraclass correlation coefficient (ICC) of 0.83 when the GAD-7 was re-administered after one week, suggesting good temporal stability.

Criterion validity was established against structured diagnostic interviews. In the original study, the GAD-7 was compared to independent mental health professional diagnoses using structured interviews. At the standard cut-point of 10, the instrument demonstrated:

• Sensitivity: 89% — meaning it correctly identified 89% of individuals who had GAD
• Specificity: 82% — meaning it correctly identified 82% of individuals who did not have GAD
• Positive likelihood ratio: 5.1
• Negative likelihood ratio: 0.13

Construct validity is supported by strong correlations with other established anxiety measures, including the Beck Anxiety Inventory (BAI), the anxiety subscale of the Symptom Checklist-90 (SCL-90), and the State-Trait Anxiety Inventory (STAI). GAD-7 scores also correlate significantly with measures of functional impairment, disability days, and healthcare utilization, confirming that higher scores reflect meaningful clinical burden.

Convergent and discriminant validity have been demonstrated: while the GAD-7 correlates moderately with depression measures such as the PHQ-9 (reflecting the well-established comorbidity between anxiety and depression), factor analyses consistently show that the GAD-7 and PHQ-9 measure distinct but related constructs.

The instrument has also shown sensitivity to change, making it suitable for tracking treatment response over time. Research supports its use as an outcome measure in both pharmacological and psychotherapy trials.

For settings where even a seven-item questionnaire may be too lengthy — such as high-volume primary care visits, emergency departments, or population-level screening programs — the GAD-2 offers an ultra-brief alternative. The GAD-2 uses only the first two items of the GAD-7:

• Feeling nervous, anxious, or on edge
• Not being able to stop or control worrying

Scores range from 0 to 6, with a cut-point of 3 or above indicating the need for further evaluation. At this threshold, the GAD-2 demonstrates a sensitivity of 86% and a specificity of 83% for generalized anxiety disorder. It also performs reasonably well as a screening tool for panic disorder, social anxiety disorder, and PTSD.

The GAD-2 is commonly used as a first-stage screen: patients who score 3 or above are then asked to complete the full GAD-7 or undergo a more thorough clinical assessment. This stepped approach balances efficiency with thoroughness and is increasingly common in integrated care models.

Despite its widespread use and strong psychometric properties, the GAD-7 has several important limitations that clinicians and patients should understand:

It is a screening tool, not a diagnostic instrument. The GAD-7 cannot diagnose generalized anxiety disorder or any other psychiatric condition. A diagnosis requires a comprehensive clinical evaluation that includes a detailed history, assessment of differential diagnoses, evaluation of medical conditions that can mimic anxiety (such as hyperthyroidism, cardiac arrhythmias, or stimulant use), and consideration of the full DSM-5-TR criteria — including the requirement that symptoms persist for at least six months and are not better explained by another condition.

It does not capture all DSM-5-TR criteria for GAD. The GAD-7 does not directly assess several associated symptoms listed in the DSM-5-TR, including muscle tension, fatigue, difficulty concentrating, and sleep disturbance. Consequently, some individuals with clinically significant GAD may score below the standard cut-point if their predominant symptoms are somatic rather than cognitive.

It is not specific to GAD. Elevated GAD-7 scores can reflect a range of anxiety disorders, depressive disorders, adjustment disorders, or stress-related conditions. A high score indicates the presence of anxiety symptoms but does not specify their etiology or diagnostic category.

Self-report bias. Like all self-report measures, the GAD-7 is subject to response biases, including minimization (underreporting symptoms due to stigma, stoicism, or lack of insight), exaggeration, and acquiescence bias. Cultural factors, health literacy, and the individual's understanding of the questions can all influence responses.

Two-week window. The GAD-7 assesses symptoms over the past two weeks only. This time frame may not capture the chronic, fluctuating nature of generalized anxiety disorder, which by definition involves symptoms persisting for six months or more. A single administration provides a snapshot, not a longitudinal picture.

Limited validation in some populations. While the GAD-7 has been validated in many populations, evidence is more limited for certain groups, including individuals with intellectual disabilities, non-English-speaking populations using translated versions that have not undergone rigorous cross-cultural validation, and very elderly populations where somatic symptoms of anxiety may overlap with medical conditions.

Comorbidity with depression. Because anxiety and depression frequently co-occur and share overlapping symptoms (such as irritability, restlessness, and difficulty concentrating), the GAD-7 should ideally be administered alongside a depression screener such as the PHQ-9 to provide a more complete clinical picture.

In clinical settings, the GAD-7 serves multiple functions that extend well beyond initial screening:

Screening and case identification. The GAD-7 is widely integrated into routine intake assessments in primary care, behavioral health clinics, and specialty medical settings. Many healthcare systems have adopted it as part of universal screening protocols, particularly in primary care, where the majority of anxiety disorders are first identified and treated. A score of 10 or above typically triggers further evaluation by the clinician, including a diagnostic interview and consideration of treatment options.

Severity assessment and treatment planning. The severity categories (minimal, mild, moderate, severe) help clinicians gauge the intensity of anxiety and inform treatment decisions. For example, mild anxiety (scores 5–9) may be appropriately managed with psychoeducation, self-help strategies, and watchful waiting, while moderate to severe anxiety (scores 10 and above) often warrants evidence-based treatment such as cognitive-behavioral therapy (CBT), pharmacotherapy, or a combination of both. Clinical practice guidelines, including those from the American Psychiatric Association and NICE (National Institute for Health and Care Excellence), reference GAD-7 severity levels in their stepped-care treatment recommendations.

Monitoring treatment response. One of the GAD-7's most valuable clinical applications is measurement-based care — the practice of systematically tracking symptom scores over time to evaluate whether treatment is working. A reduction of 5 or more points from baseline is generally considered a clinically meaningful response. Repeated administration at regular intervals (typically every 2–4 weeks during active treatment) allows clinicians and patients to make data-informed decisions about continuing, adjusting, or changing treatment approaches.

Research and population health. The GAD-7 is one of the most commonly used outcome measures in clinical trials for anxiety treatments. It is also used in epidemiological surveys, quality improvement initiatives, and population health management programs to monitor anxiety burden across patient panels.

Collaborative care and integrated settings. In collaborative care models — where primary care providers, care managers, and psychiatric consultants work together — the GAD-7 serves as a shared language for communicating about symptom severity and treatment progress. Its inclusion in electronic health records facilitates systematic tracking and population-level analytics.

The GAD-7 is a public domain instrument and is freely available for clinical and research use without licensing fees or permission requirements. This accessibility has been a major factor in its widespread adoption globally.

The instrument can be accessed through several reliable sources:

• The original publication: Spitzer RL, Kroenke K, Williams JBW, Löwe B. "A brief measure for assessing generalized anxiety disorder: the GAD-7." Archives of Internal Medicine, 2006;166(10):1092-1097. The full questionnaire is included in the article.
• The Patient Health Questionnaire (PHQ) Screeners website (phqscreeners.com) — maintained by Pfizer, this site hosts downloadable versions of the GAD-7 in multiple languages along with scoring instructions and translations.
• Electronic health record systems: Many major EHR platforms (Epic, Cerner, Athenahealth, and others) include the GAD-7 as a standard built-in questionnaire that can be administered electronically through patient portals.
• Professional organizations: The American Psychiatric Association and other clinical organizations reference and provide access to the GAD-7 in their practice resources.

Translated versions are available in over 100 languages, though clinicians should verify that any translation they use has undergone appropriate psychometric validation for their specific patient population.

If you are experiencing persistent anxiety symptoms — such as excessive worry that feels difficult to control, physical tension, restlessness, irritability, or sleep disruption — and these symptoms are interfering with your daily life, relationships, or ability to function at work or school, it is important to seek a professional evaluation.

The GAD-7 is a helpful starting point for understanding the severity of your symptoms, but it is not a substitute for a comprehensive clinical assessment. A qualified mental health professional — such as a psychiatrist, psychologist, licensed clinical social worker, or primary care provider trained in behavioral health — can conduct a thorough evaluation, determine whether your symptoms are consistent with a specific diagnosis, rule out medical conditions that can cause or worsen anxiety, and develop an individualized treatment plan.

Seek immediate help if anxiety symptoms are accompanied by thoughts of self-harm or suicide, panic attacks that feel unmanageable, or significant impairment in your ability to care for yourself or others. The 988 Suicide and Crisis Lifeline (call or text 988 in the United States) is available 24/7 for anyone experiencing a mental health crisis.

Effective, evidence-based treatments for anxiety disorders exist — including cognitive-behavioral therapy, acceptance and commitment therapy, medication management, and other approaches. Early identification and treatment are associated with better outcomes. If you have concerns about anxiety, reaching out to a healthcare provider is a meaningful and important step.